Clinical trial NCT05286008: Effect of Ultrasound-guided Transversus Abdominis Plane Block After Laparoscopic Bariatric Surgery
Official title: Impact of Ultrasound-Guided Transversus Abdominis Plane Block on Postoperative Nausea and Vomiting and Early Outcome After Laparoscopic Bariatric Surgery: a Randomized Double-Blinded Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Postoperative Nausea and Vomiting
Postoperative Pain
Keywords: Ropivacaine
Transversus abdominis plane block
opioid consumption
Dexamethasone
Lead sponsor: Tianjin Medical University General Hospital
Sponsor class: OTHER
First posted: 2022-03-18
Enrollment: 90
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To explore and compare Ultrasound-Guided Transversus Abdominis Plane Block on Postoperative nausea and vomiting and Early Outcome After Laparoscopic Bariatric Surgery To evaluate and examine TAPB can reduce the application of intraoperative and postoperative opioids and the duration of analgesia

Detailed description: Poor postoperative nausea and vomiting control is a leading factor that hinders the physical rehabilitation, and causes acute cognitive impairment and chronic pain syndrome. Recently, the multimodal analgesia strategies to minimise opioid-related side effects are highly desirable in open surgical procedures. The transversus abdominis plane block is a novel technique involving injection of local anaesthetic between the internal oblique and the transversus abdominis muscles of the abdominal wall. Although ropivacaine is most commonly used for this technique, the analgesic duration remains not dissatisfied. Herein, investigators will evaluate the efficacy of ultrasound-guided transversus abdominis plane(USG- TAP) block with ropivacaine in Laparoscopic Bariatric Surgery.

Eligibility criteria: Inclusion Criteria:

1. Subject is scheduled to undergo Laparoscopic Bariatric Surgery
2. Subject's American Society of Anesthesiologists physical status is I-III.
3. BMI\>35kg/m2
4. The subject's parent/legally authorized guardian has given written informed consent to participate

Exclusion Criteria:

1. Subject has a diagnosis of renal or liver failure.
2. Subject has a diagnosis of mental illness
3. Subject is allergy and contraindication to Ropivacaine.
4. Subject has a history of chronic pain, a history of alcohol or opioid abuse, pre-existing therapy with opioids, intake of any analgesic drug within 48 hours before surgery.
5. Subject has any contraindication for the use
6. Subject is pregnant or breast-feeding.

Primary outcomes:
measure: Postoperative nausea and vomiting
timeFrame: 72 hours after surgery
Secondary outcomes:
measure: cumulative Sufentanyl Consumption during surgery
timeFrame: during surgery
measure: cumulative Sufentanyl Consumption after surgery
timeFrame: 48 hours after surgery
measure: Time of First Postoperative Analgesic Requiremen
timeFrame: 1hour after surgery
measure: Total Dose of First Postoperative Analgesic Requirement
timeFrame: 1hour after surgery
measure: The incidence of Side Effects
timeFrame: 48 hours after surgery
measure: Apfel score
timeFrame: The 1 day before the surgery
measure: Time to ambulation
timeFrame: 12 hours after surgery
measure: Mean time until passage of flatus
timeFrame: 72 hours after surgery
measure: Diffusion area of local anesthetics after transversus abdominis plane block
timeFrame: 30 minutes after transversus abdominis plane block
measure: Normalized Area of Hyperalgesia Around the Incision
timeFrame: 48 hours after surgery
Other outcomes:
Locations:
Study officials:
affiliation: Tianjin Medical University General Hospital
name: Guolin Wang, MD
role: STUDY_DIRECTOR
References: